Biocodex SAS

The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 - The Alliance Promotion Microbiome (APM), a key player dedicated to the development, production, and commercialization of therapeutic innovations based on the microbiome, announces today its expansion across Europe and its rebranding as the European Microbiome Innovation for Health (EMIH) association. This transition marks a pivotal moment in solidifying and advancing Europe's industrial microbiome sector, with the goal of fostering medical innovation and securing a prominent global position for European stakeholders to enhance patients' health by addressing unmet medical needs. Beyond a simple change of name, the aim is to formalize the decision to operate at the European level, recognizing its paramount significance due to its critical capacity to drive positive outcomes in research and development, consequently enhancing public health. This choice is underscored by the escalating global competition and underscores the imperative to address the burgeoning realities within the maturing European landscape. This comes at a pivotal moment when the European Union is structuring and displaying major ambitions in terms of health with structuring texts such as SoHO - to be implemented - and the pharmaceutical package - to be brought to a successful conclusion - not forgetting strategic programs such as EU4Health. Each initiative carries profound implications, shaping the trajectory of leveraging the vast potential of microbiome for the health of patients and the European economy. EMIH is an independent European coalition, a public and private initiative and a non-profit organization aiming to ensure that microbiome-based medical innovations become a public health priority in the European Union. Its members are committed to advancing knowledge and the emergence of therapeutic bioproductions, diagnostics, and medical devices based on the microbiome in the field of human health, ensuring equal access through regulatory frameworks meeting the highest quality standards, while also maintaining economic balance to sustain therapeutic innovation. The EMIH believes that only major action at this level will make it possible to structure a leading microbiome sector in Europe, providing the European ecosystem with a key global position to accelerate the emergence of innovative microbiome-based therapies. Such advancements represent a profound and significant paradigm shift in the approach to healthcare for all. "European microbiome actors distinguish themselves with innovative R&D and their significant roles within the global sector. They are recognized for their pursuit of excellence and hold leadership positions in their respective fields. By uniting our efforts within EMIH, our goal is to bring microbiome medical innovation to one of the most promising sectors and to prioritize it within the European Union's public health agenda. Our ambition is to make these advancements accessible to all patients. Thus, we invite all European entities engaged in microbiome research to submit their applications to join EMIH. Together, let's make microbiome the flagship of European health innovation," states Hervé Affagard, President-elect of EMIH. About European Microbiome Innovation for Health (formerly known as Alliance Promotion Microbiome-APM) EMIH is an independent coalition within the European Union, the United Kingdom, and Switzerland, currently comprising 20 major players from the public and private sectors. From the laboratory to the patient's bedside, EMIH covers the entire value chain of the microbiome industry. Its goal is to position Europe as a global leader in the development, production, and commercialization of microbiome-based therapeutic innovations. EMIH members include Bioaster, Biocodex, Biofortis, Biose Industrie, Cynbiome, Eligo Bioscience, Ferring Pharmaceuticals, GMT Science, INRAE, Lallemand Health Solutions, Lyonbiopôle, Pelican Health, MaaT Pharma, Microbiome Foundation, Polepharma, Medicen Paris Région, Nexbiome, Novobiome, Seventure Partners, and Skyepharma. Contacts for European Microbiome Innovation for Health Media - E-mail: pri@frenchmicrobiome.orgMemberships & Applications - E-mail: contact@frenchmicrobiome.org

MONTREAL, April 30, 2024 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant proposals from innovative researchers at Canadian institutions. Biocodex Microbiota Foundation is pleased to announce the initiation of its annual call for projects: the 2024 National Grant in Canada - a unique opportunity to delve into the fascinating world of the human microbiome. The Foundation is dedicated to fostering investigations on microbiota and their intricate interactions with various human pathologies. In line with this commitment, the Foundation is calling for "non-profit" research projects and will award selected projects that demonstrate exceptional potential and innovation. About the National Grant The 2024 National Grant in Canada will provide a substantial award of €25,000 to an applicant from a Canadian institution or university with a 1 to 2-year long research project centered around the theme of microbiome in human health and diseases. This initiative reflects the Foundation's mission to support groundbreaking research that contributes to a deeper understanding of the role of microbiota in maintaining or compromising human health. Application Details - Join Us in Advancing Microbiota Research! Interested researchers are invited to submit their applications no later than August 31st, 2024. The independent scientific committee overseeing the selection process will announce their decision by September 30th, 2024. More information about eligibility criteria and the application process can be found on the official Biocodex Microbiota Foundation website: National Research Grant - Call for Projects Canada 2023 Grant Winner - Dr. Charlene Roussel As we embark on this new grant cycle, we also take a moment to celebrate the success of Dr. Charlene Roussel, the distinguished winner of the 2023 National Grant. Dr. Roussel, affiliated with the Institute of Nutrition and Functional Foods (INAF) at Laval University and newly appointed Assistant Professor within the School of Pharmaceutical Sciences at the University of Ottawa. She was recognized for her outstanding research on microbial interactions with a focus on enhancing human health, particularly in the realm of women's health. Dr. Roussel's innovative work exemplifies the kind of impactful research the Biocodex Microbiota Foundation aims to support. Her dedication to advancing our understanding of microbiota and their role in human health aligns perfectly with the Foundation's mission. For more information about Dr. Charlene Roussel and her award-winning research, please visit 2023 National Research Grant Winner - Dr. Charlene Roussel. About BiocodexFounded in France in 1953, Biocodex is a multinational company, based on the highest scientific and manufacturing standards. Biocodex currently holds 17 subsidiaries (including Biocodex Canada Inc. based in Montréal – Quebec) and multiple long-term partnerships spanning more than 115 countries. With over 70 years of successful international operations, the mission of Biocodex is to remain a worldwide leader in expertise within the microbiota realm. www.biocodex.ca/en/ About Biocodex Microbiota FoundationThe Biocodex Microbiota Foundation is a non-profit, general interest organization that supports research into microbiota and their interaction with various pathologies. Both foundational and applied research grants are awarded. Projects investigating the implication of microbiota in human health are selected annually by committees of independent international scientists. www.biocodexmicrobiotafoundation.com Contact: grant.microbiota@biocodex.ca Follow us on LinkedIn: Biocodex Microbiota Foundation A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59fd7b87-c04d-4b8f-a12b-79dd675ed2b5

PARIS--( BUSINESS WIRE )--Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement. My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting. Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders. On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development. Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being." Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.” About Biocodex Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value. Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics. The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022. www.biocodex.com About My Health My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs. Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC). www.myhealth-biotech.com